Clinical research company George Clinical said on Thursday that it is working with Saint Luke's Mid America Heart Institute on a new study to explore whether SGLT inhibitor dapagliflozin can prevent disease progression in patients hospitalized with COVID-19 and at high risk for complications due to pre-existing cardio metabolic risk factors.
The global 'DARE-19' study will include 900 patients with approximately half of those coming from the United States and the remainder from other countries with high prevalence of COVID-19.
Study enrolment has started in the Kansas City metropolitan area at Saint Luke's Hospital of Kansas City and other other hospitals around the US.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal